The Clinical Application of ATM-AVI in Patients with CRE Infections, including MBL-Producing CRE Grant

The Clinical Application of ATM-AVI in Patients with CRE Infections, including MBL-Producing CRE Grant

Status: ACTIVE
Funder: Pfizer, Inc.
Amount: Up to US $35,000
Last Updated: October 10, 2025

Summary

This project focuses on the clinical application of ATM-AVI to treat carbapenem-resistant Enterobacterales (CRE) infections, including MBL-producing strains, particularly in China. The program evaluates treatment effectiveness, patient demographics, microbiological outcomes, and healthcare resource utilization across various departments such as ICU and transplantation. By assessing ATM-AVI's role in improving patient outcomes, this initiative aligns with Pfizer's commitment to innovative healthcare solutions.

Overview

Pfizer Inc. Pfizer's purpose is breakthroughs that change patients’ lives. We pursue that goal relentlessly and innovate every day to make the world a healthier place. It was Charles Pfizer’s vision at the beginning and it holds true today. Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for pro-innovation/pro-patient policies. The Clinical Application of ATM-AVI in Patients with CRE Infections, including MBL-Producing CRE Overview This competitive program aims to evaluate the clinical effectiveness and impact of ATM-AVI (aztreonam–avibactam) 1-2 in treatment of carbapenem-resistant Enterobacterales (CRE) infections, including Metallo-β-lactamase (MBL) CRE in China, with a focus on departments such as Intensive Care Unit (ICU), solid organ transplantation, hematology, respiratory, etc. The program will evaluate ATM-AVI treatment patterns, patient demographics, microbiological characteristics, clinical and microbiological outcomes, and healthcare resource utilization.

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.